Patents for C12N 7 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof (26,637)
03/2003
03/27/2003WO2002055544A3 Fibrin binding polypeptides useful inter alia in medical imaging processes
03/27/2003WO2002044374A3 Flea gaba receptor subunit nucleic acid molecules, proteins and uses thereof
03/27/2003WO2002009750A3 Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene
03/27/2003WO2001083794A3 Dna transfection system for the generation of infectious influenza virus
03/27/2003US20030059943 Inhibition of gene expression in preferential cell; obtain cells, infect with viral particles, recover infected cells, express viral sequences, monitor adjustment in gene expression
03/27/2003US20030059934 Artificial chromosomes comprising EHV sequences
03/27/2003US20030059873 Hepatitis virus for use in the diagnosis and prevention of viral diseases in birds and humans
03/27/2003US20030059799 Modified DNA molecule, recombinant containing the same, and uses thereof
03/27/2003US20030059455 A defective recombinant adenovirus including at least one DNA sequence coding for all or an active part of a superoxide; useful for treating and/or preventing Parkinson's disease, Alzheimer's disease, Huntington's disease etc.
03/27/2003US20030059401 Composition and method for causing photodynamic damage to target cells
03/27/2003CA2492826A1 Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
03/27/2003CA2460778A1 Methods for testing and producing (-) strand rna virus vectors with reduced particle formation ability
03/27/2003CA2460157A1 Site-specific recombinase based method for producing adenoviral vectors
03/26/2003EP1295952A2 Methods for screening for transdominant effector peptides and RNA molecules
03/26/2003EP1294952A1 Hiv-1 reporter viruses and their use in assaying anti-viral compounds
03/26/2003EP1294918A2 Replication deficient adenoviral tnf vector
03/26/2003EP1294892A2 Assembly of wild-type and chimeric influenza virus-like particles (vlps)
03/26/2003EP1294886A2 THREE-DIMENSIONAL MODEL OF A Fc REGION OF AN IGE ANTIBODY AND USES THEREOF
03/26/2003EP1294885A2 B7-like molecules and uses thereof
03/26/2003EP1294858A2 Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes
03/26/2003EP1294745A2 Antimicrobial peptides and methods of use thereof
03/26/2003EP0431128B1 Vector coding for self-assembled, defective, non-self-propagating viral particles
03/26/2003CN1406277A Recombinant attenuation of PRRSV
03/26/2003CN1405310A Method for producing medicine using silkworm expressed numan epidermal growth factor
03/26/2003CN1405309A Method for preparing medicine using silkworm expressed human beta interferon
03/26/2003CN1405308A Method for producing medicine using silkworm expressed human alpha2b interferon
03/26/2003CN1404874A Method for preparing thermal purifying-inactivating vaccine to bleeding of double-adicity vero cell kidney syndrome and use thereof
03/26/2003CN1103603C Inactivated respiratory syncytial viral vaccines
03/25/2003US6538182 Genetic modification of plants to control age-related or environmental stress-induced senescence; use in extending shelf-life and slowing spoilage of plant cuttings, flowers, seeds, fruits, vegatables, or leaves
03/25/2003US6537793 Method of separating viral particles
03/25/2003US6537594 Vaccina virus comprising cytokine and/or tumor associated antigen genes
03/25/2003US6537557 Strain 341750 PDK-6
03/25/2003US6537540 Administering recombinant adeno-associated virus vector; polynucleotide encoding fusion polypeptide with extracellular domain of the TNF receptor and a constant domain of an IgG1 molecule
03/20/2003WO2003023042A1 Recombinant mva capable of expressing structural hcv antigens
03/20/2003WO2003023041A2 Infectious and attenuated bovine viral diarrhea virus clone; methods for their production and use
03/20/2003WO2003023040A2 Vaccinia virus mva-e3l-knockout-mutants and use thereof
03/20/2003WO2003023032A2 High throughput directed evolution by rational mutagenesis
03/20/2003WO2003023026A1 Alphavirus replicon vector systems
03/20/2003WO2003023025A1 Multiplication of viruses in a cell culture
03/20/2003WO2003023021A2 Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture
03/20/2003WO2003022886A1 Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses
03/20/2003WO2003022878A2 Subunit respiratory syncytial virus vaccine preparation
03/20/2003WO2003022202A2 Compositions and methods for treatment of cancer
03/20/2003WO2002092786A3 A helper dependent adenoviral vector system and methods for using the same
03/20/2003WO2002038726A3 Paramyxovirus vector for gene transfer to the cardiovascular system
03/20/2003US20030054555 Generation of adenoviral vectors; obtain nucleotide sequences, incubate with vector, expose to recombinases, recover vector
03/20/2003US20030054553 Transgenic cell for the propagation of adenoviral vectors
03/20/2003US20030054548 Lentiviral packaging constructs
03/20/2003US20030054505 Infectious Respiratory Syncytial Viral particle for use as gene transfer tool in genetic engineering
03/20/2003US20030054495 Chimaeric phage for use as tool in genetic engineering
03/20/2003US20030054492 Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
03/20/2003US20030054382 Infection of eukaryotic cells with viruses in vitro
03/20/2003US20030054341 Viral nucleotide sequences for use in diagnosis, prevention and treatment of viral diseases
03/20/2003US20030053990 Virus vectors and methods of making and administering the same
03/20/2003US20030053988 Genetic engineering; culture product; process control
03/20/2003US20030052839 Stabilized viral envelope proteins and uses thereof
03/20/2003CA2462574A1 Subunit respiratory syncytial virus vaccine preparation
03/20/2003CA2460269A1 Alphavirus replicon vector systems
03/20/2003CA2459769A1 Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses
03/20/2003CA2458543A1 Compositions and methods for treatment of cancer
03/20/2003CA2457441A1 Infectious and attenuated bovine viral diarrhea virus clone; methods for their production and use
03/20/2003CA2456561A1 Multiplication of viruses in a cell culture
03/19/2003EP1292616A2 Nucleic acids encoding a regulator of g protein signaling, rgs18, and uses thereof
03/19/2003EP1292615A2 Modified morbillivirus v proteins
03/19/2003EP1292329A1 Manipulation of negative stranded rna viruses by rearrangement of their genes and uses thereof
03/19/2003EP1292328A1 Chimeric human papillomavirus (hpv) l1 molecules and uses therefor
03/19/2003EP0595935B1 Papillomavirus Vaccine
03/19/2003CN1403573A Method of raising the yield of insect baculovirus with insect juvenoid
03/19/2003CN1402974A Virus deactivating method with immobilized solvent or immobilized solvent-detergent
03/18/2003USRE38037 Modular semiconductor power device
03/18/2003US6534066 Inactivated vaccine against feline calicivirosis
03/18/2003US6534051 Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
03/18/2003CA2277995C Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces
03/13/2003WO2003020958A2 Campylobacter typing
03/13/2003WO2003020930A1 IDENTIFICATION AND USE OF MAMMALIAN p21 INHIBITORS
03/13/2003WO2003020893A2 New adenovirus type 7 vectors
03/13/2003WO2003020879A2 Cells and methods for propagating adenoviral vectors
03/13/2003WO2003020876A2 Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
03/13/2003WO2003020308A1 Chicken anemia virus vaccine from cell line
03/13/2003WO2003020204A2 Detection of bovine viral diarrhea virus in tissue samples
03/13/2003WO2002091997A3 Oncolytic virus therapy
03/13/2003WO2002085932A3 Constructs and methods for expression of recombinant hcv envelope proteins
03/13/2003WO2002068654A3 Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
03/13/2003WO2002020571A3 Attenuated hiv strains and use thereof
03/13/2003WO2002018909A3 Single riser/single capillary blood viscometer using mass detection or column height detection
03/13/2003WO2002014471A3 A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
03/13/2003WO2002004494A3 Process for the selection of hiv-1 subtype c isolates, selected hiv-1 subtype isolates, their genes and modifications and derivatives thereof
03/13/2003WO2001083797A3 Polynucleotides for use in recombinant adeno-associated virus virion production
03/13/2003WO2001081375A3 Dna & protein binding miniature proteins
03/13/2003US20030051259 Packaging cells
03/13/2003US20030050463 Nucleotide sequences encoding fusion protein for use in generation of vaccines against viral diseases
03/13/2003US20030050439 Polypeptide for use in the treatment of tumors and warts
03/13/2003US20030050271 Infecting the vasculature of an organ or a tissue other than a liver with a vector carrying genetic material of interest for a time under conditions which protect from ischemic damage
03/13/2003US20030049845 Viral envelope protein for use as tools gene therapy
03/13/2003US20030049844 Recombinant canine herpesviruses
03/13/2003US20030049843 Gene delivery vectors with cell type specificity for mesenchymal stem cells
03/13/2003US20030049831 Protein for use in the prevention of infections
03/13/2003US20030049830 Herpes virus complementing cell line
03/13/2003US20030049829 Concentration and lysis of adenovirus-infected cells in a single unit operation
03/13/2003US20030049825 Nervous necrosis virus protein